With the price of Mounjaro set to almost triple in the UK, there are fears more and more people will turn to counterfeits.

What goes up must come down — here are the major drugs falling the hardest at the top companies so far this year.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

S&P 500, Eli Lilly and Company, Nomura Holdings Inc ADR, The Health Care Select Sector SPDR® Fund. Read 's Market Analysis on Investing.com ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers.

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...